Financial News · Live Terminal

Page 569 of 692

Jefferies Adjusts Price Target on GE Healthcare Technologies to $90 From $105

GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $60.04, Change: $+0.56, Percent Change: +0.93%

$GEHC

Wire146d ago

Raymond James Adjusts Regeneron Pharmaceuticals Price Target to $902 From $910

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.Price: $705.61, Change: $+19.25, Percent Change: +2.80%

$REGN

Wire146d ago

Leerink Partners Adjusts Regeneron Pharmaceuticals Price Target to $792 From $873

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.Price: $705.61, Change: $+19.25, Percent Change: +2.80%

$REGN

Wire146d ago

Barclays Adjusts Regeneron Pharmaceuticals Price Target to $917 From $923

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.Price: $705.61, Change: $+19.25, Percent Change: +2.80%

$REGN

Wire146d ago

Morgan Stanley Adjusts Regeneron Pharmaceuticals PT to $788 From $796

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.Price: $705.61, Change: $+19.25, Percent Change: +2.80%

$REGN

Wire146d ago

JPMorgan Adjusts Price Target on GE Healthcare Technologies to $65 From $80

GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $60.03, Change: $+0.54, Percent Change: +0.91%

$GEHC

Wire146d ago

Wells Fargo Adjusts Price Target on GE Healthcare Technologies to $75 From $97

GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $60.03, Change: $+0.54, Percent Change: +0.91%

$GEHC

Wire146d ago

Nutrien Could Benefit From Rising Risk of Market Tightness, BofA Says

Nutrien (NTR) could benefit from rising risk of market tightness into H2 and 2027 as the Strait of Hormuz remains closed, BofA Securities said in a note Thursday."There is a narrow window for global fertilizer trade to normalize before keybuying periods in India and Brazil begin, and a prolonged Strait of Hormuz (SOH) blockade increasingly risks missing that window," the report said.The note said there is upside risk to fertilizer price forecast in H2 and 2027 grain markets should buyers get shorted on product."To be clear, we are not there yet, but the risk is growing, and Nutrien shares still trade at pre-conflict levels," the report said, adding that this creates an opportunity for investors looking for conflict exposure.BofA upgraded Nutrien to buy from neutral with a price target of $82.Price: $75.38, Change: $+1.25, Percent Change: +1.69%

$NTR

Wire146d ago

Barclays Adjusts Garmin's Price Target to $238 From $240, Keeps Equalweight Rating

Garmin (GRMN) has an average rating of hold and mean price target of $260.33, according to analysts polled by FactSet.Price: $249.41, Change: $-3.68, Percent Change: -1.45%

$GRMN

Wire146d ago

Teradyne Results Reflect Expectations Issue as AI Networking Outlook Tempered, Morgan Stanley Says

Teradyne's (TER) results reflect an "expectations issue" rather than a miss, as investor optimism around AI networking and related test opportunities needs to be tempered, even as Silicon Photonics/Co-Packaged Optics TAM grows to $300-700 million over the medium term, Morgan Stanley said in a Thursday note.However, the brokerage said networking expectations will need to be tempered, adding that Teradyne's comment that market share is balanced with competitor Advantest was "discouraging," particularly as networking has historically been a stronghold for the company.Morgan Stanley also flagged caution on the Nvidia (NVDA) GPU opportunity, noting that while Teradyne has secured initial production test orders, the longer-term scale and share gains remain uncertain and are not fully reflected in investor expectations.Teradyne revised its revenue outlook to reflect a slightly more back-half weighted profile for 2026, with full-year revenue now expected at $4.14 billion to $4.51 billion. The low end reflects potential hiccups in AI data center build-out, while the high end assumes continued strength across compute, networking and memory demand.Morgan Stanley raised its 2026 revenue and earnings per share estimates to $4.75 billion and $8.03 from $4.73 billion and $7.25. It also lifted its 2027 estimates to $6.30 billion in revenue and $11.37 in EPS from $6.30 billion and $11.05.The firm lifted its price target on the stock to $387 from $376 and kept its equalweight rating.Shares of Teradyne were up more than 14% in Thursday trading.Price: $350.14, Change: $+43.81, Percent Change: +14.30%

$TER

Wire146d ago

Garmin Beats Q1 Expectations as Fitness Segment Surges, Morgan Stanley Says

Garmin (GRMN) posted modestly better-than-expected Q1 results, with the fitness segment again standing out, Morgan Stanley said Wednesday in a report.The fitness business delivered "outsized growth," with revenue acceleration at an 11-year high and gross margins expanding by 470 basis points, the report said.Garmin's unchanged full-year outlook is "typical this early in the year," with room for estimates to move higher, Morgan Stanley said. Management also does not expect a deterioration in high-end consumer spending, with demand remaining strong and resilient to geopolitical tensions, the report said.While inflation in component costs is expected to have only a small effect this year, Morgan Stanley said it will likely become a headwind in 2027.The firm raised its 2026 EPS estimate to $9.80 from $9.50 on better-than-expected profitability. Its 2027 EPS forecast is now $10.36, down 1%, partly reflecting expectations for higher component costs next year.Morgan Stanley lowered its price target on Garmin stock to $249 from $252 and maintained its equal-weight rating.Price: $249.33, Change: $-3.75, Percent Change: -1.48%

$GRMN

Wire146d ago

Barclays Adjusts MGM Resorts International PT to $39 From $37

MGM Resorts International (MGM) has an average rating of overweight and mean price target of $43.94, according to analysts polled by FactSet.Price: $39.19, Change: $-0.09, Percent Change: -0.22%

$MGM

Wire146d ago

Wells Fargo Adjusts MGM Resorts International Price Target to $33 From $30

MGM Resorts International (MGM) has an average rating of overweight and mean price target of $43.94, according to analysts polled by FactSet.Price: $39.19, Change: $-0.09, Percent Change: -0.22%

$MGM

Wire146d ago

Macquarie Adjusts MGM Resorts International PT to $48 From $46

MGM Resorts International (MGM) has an average rating of overweight and mean price target of $43.94, according to analysts polled by FactSet.Price: $39.19, Change: $-0.09, Percent Change: -0.22%

$MGM

Wire146d ago

Goldman Sachs Adjusts Regeneron Pharmaceuticals Price Target to $968 From $967

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.Price: $706.67, Change: $+20.31, Percent Change: +2.96%

$REGN

Wire146d ago

Piper Sandler Adjusts Price Target on GE Healthcare Technologies to $74 From $88

GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $59.98, Change: $+0.49, Percent Change: +0.82%

$GEHC

Wire146d ago

Market Chatter: Markel Group Pushed by Jana to Divest Ventures, Repurchase $2 billion of Stock

Markel Group (MKL) is being urged by Jana Partners to divest its venture arm and to repurchase $2 billion of its shares to boost the stock price, Bloomberg reported Thursday, citing a letter sent to Markel's board that it reviewed.Markel and Jana didn't immediately reply to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $1775.87, Change: $+16.66, Percent Change: +0.95%

$MKL

Wire146d ago

Raymond James Adjusts SLB Price Target to $62 From $58

SLB (SLB) has an average rating of overweight and mean price target of $60.86, according to analysts polled by FactSet.Price: $56.69, Change: $+0.98, Percent Change: +1.77%

$SLB

Wire146d ago

Citigroup Adjusts SLB Price Target to $68 From $59

SLB (SLB) has an average rating of overweight and mean price target of $60.86, according to analysts polled by FactSet.Price: $56.67, Change: $+0.97, Percent Change: +1.74%

$SLB

Wire146d ago

Bernstein Adjusts Regeneron Pharmaceuticals PT to $916 From $913

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.Price: $706.12, Change: $+19.76, Percent Change: +2.88%

$REGN

Showing 11361-11380 of 13825